Cantor Fitzgerald Increases Earnings Estimates for AbbVie

AbbVie Inc. (NYSE:ABBV - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for AbbVie in a report issued on Wednesday, October 15th. Cantor Fitzgerald analyst C. Gould now forecasts that the company will post earnings of $10.82 per share for the year, up from their previous estimate of $10.59. Cantor Fitzgerald has a "Overweight" rating and a $250.00 price target on the stock. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

A number of other research firms have also recently weighed in on ABBV. Bank of America boosted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Berenberg Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating and boosted their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. UBS Group set a $251.00 price objective on shares of AbbVie in a research report on Friday, October 3rd. Hsbc Global Res cut shares of AbbVie from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 1st. Finally, Wells Fargo & Company boosted their target price on shares of AbbVie from $240.00 to $260.00 and gave the company an "overweight" rating in a research note on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $233.35.

AbbVie Trading Up 0.2%

ABBV stock opened at $226.77 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie has a twelve month low of $163.81 and a twelve month high of $244.81. The stock has a market capitalization of $400.60 billion, a price-to-earnings ratio of 107.99, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. The firm's fifty day simple moving average is $217.28 and its two-hundred day simple moving average is $197.43.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter last year, the firm earned $2.65 EPS. The company's revenue was up 6.6% on a year-over-year basis.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Wednesday, October 15th. AbbVie's payout ratio is currently 312.38%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AbbVie

Several large investors have recently modified their holdings of the business. Ellenbecker Investment Group increased its stake in AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock worth $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA increased its stake in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock worth $3,562,000 after purchasing an additional 45 shares during the period. Matthew Goff Investment Advisor LLC increased its stake in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock worth $4,066,000 after purchasing an additional 45 shares during the period. Willner & Heller LLC increased its stake in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company's stock worth $1,759,000 after purchasing an additional 46 shares during the period. Finally, Hobart Private Capital LLC increased its stake in AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company's stock worth $261,000 after purchasing an additional 48 shares during the period. Institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.